Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more
Dr. Abbey Spoke About Vitrectomy and Light Adjustable Lenses at ASRS 2026
Texas Retina’s Ashkan Abbey, MD, FASRS, FAAO, participated in a panel discussion on the impact of vitrectomy on light adjustable lenses before final laser lock-in in post-cataract surgery patients at the 44th
read more
10 New Clinical Trials Available at Texas Retina
In the last two decades, medical researchers have made significant advances in the diagnosis and treatment of retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision.
read more
Texas Retina Research Team Publishes New Study on Wet AMD Treatment
Texas Retina’s Ashkan Abbey, MD; Paige Abril, BS; and Rachel McCullough, BS, recently published a retrospective study in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina titled, “Outcomes of Intravitreal Aflibercept
read more
Dr. Abbey Discusses Latest Dry AMD Treatment Research on New Podcast Episode
While anti-VEGF injections are widely used to treat patients with wet age-related macular degeneration (AMD), there have been limited treatment options available for dry AMD other than AREDS vitamin formulations and lifestyle
read more
Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Texas Retina Honors Founder Dr. Vaiser with Donation to Retina Foundation
On behalf of the entire Texas Retina team, Gary Edd Fish, MD, recently presented a $2,000 donation to the Retina Foundation to honor the 90th birthday of one of Texas Retina’s founders,
read more
Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read more
Dr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting
Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual
read more
Dr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more